| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $9.8M | 0.01% | 340.40K | +152% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a STAA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 13, 2026 | Michna MagdaOfficer | Conversion of Exercise of derivative security at price 26.18 per share. | 6.6K | $28.80K |
| Aug 13, 2026 | Foust WarrenChief Executive Officer | — | 11K | — |
| Aug 13, 2026 | Andrews Deborah JChief Financial Officer | — | 5.2K | — |
| Jul 30, 2026 | Foust WarrenChief Executive Officer | — | 20.8K | — |
| Jul 30, 2026 | Andrews Deborah JChief Financial Officer | — | 34.7K | — |
| Jun 17, 2026 | Butcher Arthur CDirector | — | 5.3K | — |
| Jun 17, 2026 | Jiang WeiDirector | — | 10.7K | — |
| Jun 17, 2026 | Silverman Louis EDirector | — | 10.7K | — |
| Jun 11, 2026 | Zhou Lilian YanshengDirector | Stock Award(Grant) at price 28.29 per share. | 3.5K | $99.86K |
| May 14, 2026 | Michna MagdaOfficer | Stock Award(Grant) at price 0.00 per share. | 19.8K | — |
| May 14, 2026 | Foust WarrenChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 33K | — |
| May 14, 2026 | Andrews Deborah JChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 15.7K | — |
| Mar 12, 2026 | Michna MagdaOfficer | — | 23.8K | — |
| Mar 12, 2026 | Foust WarrenChief Executive Officer | — | 37.5K | — |
| Mar 12, 2026 | Broadwood Partners, L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 17.52 - 18.62 per share. | 670.2K | $12.27M |
| Jan 11, 2026 | Jiang WeiDirector | — | 21K | — |
| Jan 8, 2026 | Broadwood Partners, L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 22.05 per share. | 27.5K | $606.14K |
| Jan 7, 2026 | Broadwood Partners, L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 21.01 - 22.38 per share. | 406.7K | $8.82M |
| Nov 20, 2025 | Broadwood Partners, L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 26.42 - 27.86 per share. | 1.50M | $41.06M |
| Nov 11, 2025 | Jiang WeiDirector | — | 21K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -17.9 | 5.0 | -6.0 | 41.0 | 13.4 | -4.0 | -15.1 | -7.3 | 0.1 | -4.1 | −6.1% | ||
| 2025 | -0.4 | -27.7 | 0.7 | 3.6 | -2.5 | -5.8 | 6.8 | 52.7 | -1.8 | -3.7 | 2.6 | -13.0 | −4.9% |
| 2024 | -10.3 | 11.5 | 22.5 | 20.1 | -9.6 | 14.6 | -13.4 | -19.8 | 12.3 | -22.0 | 0.4 | -16.5 | −22.2% |
| 2023 | 45.3 | -21.5 | 15.5 | 10.2 | -17.7 | -9.4 | 4.2 | -20.8 | -7.3 | 4.1 | -25.0 | -0.5 | −35.7% |
| 2022 | -20.4 | 9.1 | 0.7 | -28.6 | 15.5 | 7.6 | 13.8 | 17.2 | -25.4 | 0.5 | -19.4 | -15.0 | −46.8% |
| 2021 | 29.5 | 1.4 | 1.3 | 30.0 | 6.6 | 4.4 | -16.1 | 20.8 | -16.8 | -7.8 | -19.6 | -4.1 | +15.2% |
| 2020 | -4.4 | -6.7 | 2.8 | 18.8 | 1.3 | 58.6 | -5.4 | -17.6 | 18.0 | 28.2 | -1.7 | 11.2 | +125.2% |
| 2019 | 12.0 | 3.0 | -7.1 | -5.0 | -28.7 | 26.8 | -0.2 | 2.7 | -14.4 | 27.2 | 12.4 | -4.6 | +10.2% |
| 2018 | 1.3 | 0.0 | -5.7 | 9.8 | 83.1 | 4.2 | -0.5 | 54.6 | 0.6 | -16.4 | -5.2 | -16.0 | +105.9% |
| 2017 | -8.8 | 0.5 | -1.5 | 6.1 | -12.0 | 18.0 | -5.1 | 16.6 | 4.2 | 6.4 | 30.9 | -10.7 | +42.9% |
| 2016 | -8.5 | -4.6 | 18.6 | 4.3 | -29.6 | 1.5 | 24.1 | 28.4 | 7.1 | -10.1 | 28.4 | 0.0 | +52.0% |
| 2015 | -34.1 | 14.3 | 8.3 | 19.1 | 5.5 | 3.4 | -9.2 | -8.9 | -2.9 | 5.0 | 2.9 | -14.9 | −21.6% |
| 2014 | 1.4 | -13.8 | 32.8 | -9.5 | -9.3 | 8.9 | -23.4 | -10.6 | -7.6 | -10.0 | -3.8 | -1.1 | −43.7% |
| 2013 | -7.2 | -4.8 | 4.5 | 24.0 | 27.5 | 14.0 | 3.5 | 20.7 | 6.7 | -2.2 | -4.7 | 28.3 | +165.4% |
| 2012 | 3.8 | -4.2 | 3.8 | 1.3 | -22.6 | -8.5 | -33.8 | 27.4 | 15.4 | -14.8 | -10.2 | 5.5 | −41.8% |
| 2011 | -14.3 | 14.7 | -7.2 | -0.4 | 6.7 | -10.5 | -14.2 | 80.0 | -4.8 | 15.4 | 9.2 | 6.7 | +72.0% |
| 2010 | 10.6 | 9.6 | 1.6 | 33.2 | 2.2 | 10.0 | 5.6 | -24.3 | 18.4 | -2.6 | 1.5 | 14.0 | +96.8% |
| 2009 | -18.1 | -35.9 | -20.0 | -13.0 | 13.8 | 143.4 | 12.0 | 9.3 | 38.3 | -5.4 | -3.1 | -17.1 | +30.3% |
| 2008 | -9.5 | -2.9 | 11.2 | -8.9 | 42.6 | -7.5 | 32.3 | 33.4 | -17.9 | -45.2 | -26.0 | 30.8 | −9.8% |
| 2007 | -1.1 | -11.1 | -10.6 | -7.8 | -10.8 | -15.7 | -4.5 | -19.7 | 2.4 | 3.3 | -9.0 | -6.4 | −62.3% |
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Buy / hold / sell counts